Severe adverse events frequently occur in patients treated with sorafenib, whereas some patients have suboptimal response to sorafenib. We aimed to evaluate the association of sorafenib-induced toxicities and clinical outcomes with the pharmacokinetics of sorafenib in patients with hepatocellular carcinoma (HCC).
This was a retrospective, observational study in which 26 HCC patients who had been treated with sorafenib were enrolled between September 2010 and March 2015. The association between trough sorafenib concentration and occurrence of grade ≥ 3 toxicities was evaluated. In addition, we estimated the association of trough sorafenib concentration with overall survival (OS).
The median sorafenib concentration was 2.91 μg/mL (range 0.74–8.8 μg/mL). Based on the receiver operating characteristic curve, the threshold value of the trough sorafenib concentration for predicting grade ≥ 3 toxicities and responder (complete response or partial response at best response, or stable disease for ≥ 3 months) was 3.45 μg/mL [area under the curve (AUC) 0.74, 95% confidence interval (CI) 0.54–0.93; p <0.05] and 1.40 μg/mL (AUC 0.97, 95% CI 0.97–1.00; p <0.05), respectively. OS of patients with sorafenib 1.40–3.45 µg/mL had a tendency to be longer than those of patients administered < 1.40 μg/mL and ≥ 3.45 μg/mL [median 17.8 months (1.40–3.45 μg/mL) vs. 5.3 months (< 1.40 μg/mL) and 9.5 months (≥ 3.45 μg/mL)].
From results of this study, we proposed that the target range of sorafenib may be a trough concentration of 1.40–3.45 μg/mL in patients with HCC.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR (2018) Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev 68:16–24
Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L et al (2018) Ten years of sorafenib in hepatocellular carcinoma: are there any predictive and/or prognostic markers? World J Gastroenterol 24:4152–4163
Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P (2017) Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials. J Clin Oncol 35:622–628
Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J (2017) Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol 67:999–1008
McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A et al (2018) Sorafenib as first-line therapy in patients with advanced Child–Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer 105:1–9
Terada T, Noda S, Inui K (2015) Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther 152:125–134
Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K et al (2015) Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma. Clin Genitourin Cancer 13:350–358
Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300
Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755–762
Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60
Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S et al (2014) Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Dis 32:705–710
Noda S, Shioya M, Hira D, Fujiyama Y, Morita SY, Terada T (2013) Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Cancer Chemother Pharmacol 72:269–272
Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S (2016) Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res 46:951–963
Boudou-Rouquette P, Ropert S, Mir O, Coriat R, Billemont B, Tod M et al (2012) Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist 17:1204–1212
Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O et al (2012) Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One 7:e42875
Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J et al (2012) Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 7:e37563
Kudo M (2017) Molecular targeted agents for hepatocellular carcinoma: Current status and future perspectives. Liver Cancer 6:101–112
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66
Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M et al (2018) Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Investig New Drugs 36:332–339
Uchikawa S, Kawaoka T, Aikata H, Kodama K, Nishida Y, Inagaki Y et al (2018) Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res 48:814–820
Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851–11858
Goto H, Kitagawa N, Sekiguchi H, Miyagi Y, Keino D, Sugiyama M et al (2017) The Collagen gel droplet-embedded culture drug sensitivity test in relapsed hepatoblastoma. J Pediatr Hematol Oncol 39:395–401
Fukudo M, Ito T, Mizuno T, Shinsako K, Hatano E, Uemoto S et al (2014) Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. Clin Pharmacokinet 53:185–196
First of all, we thank all the patients that were willing to participate in this study. Furthermore, we would like to thank the hospital staff in acquiring the data.
This work was supported in part by grants from JSPS KAKENHI (Grant Numbers-JP18H00400), from the Research Foundation for Pharmaceutical Science, and from the Nakatomi Foundation.
Conflict of interest
All authors declare no conflict of interest that might be relevant to the contents of this manuscript.
This study protocol was approved by the Institutional Review Board of Shiga University of Medical Science. All patients gave written informed consent for the use of their blood sample and medical information for research.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Noda, S., Hira, D., Osaki, R. et al. Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. Cancer Chemother Pharmacol 86, 129–139 (2020). https://doi.org/10.1007/s00280-020-04105-0
- Hepatocellular carcinoma
- Personalized pharmacotherapy